Sienna Biopharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 4,983,333 shares of common stock of Sienna Biopharmaceuticals, Inc., including shares sold pursuant to…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Kala Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public offering of common stock of Kala Pharmaceuticals, Inc. The…
Davis Polk Advises Mitsubishi Tanabe Pharma on Its Acquisition of NeuroDerm
Davis Polk is advising Mitsubishi Tanabe Pharma Corporation on its approximately $1.1 billion acquisition of NeuroDerm Ltd. The transaction, which is expected to close in the fourth quarter…
Akcea Therapeutics Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 17,968,750 shares of common stock of Akcea Therapeutics, Inc., including shares sold pursuant to the…
Mersana Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $75 million initial public offering of common stock of Mersana Therapeutics…
Jounce Therapeutics, Inc. Initial Public Offering
Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics,…
Davis Polk Advises Roche on Its Sale of Florence, South Carolina, Manufacturing Site to Patheon
Davis Polk is advising Roche Holding Ltd. in connection with the sale of an active pharmaceutical ingredients manufacturing facility in Florence, South Carolina, to Patheon N.V. Under the…
iRhythm Technologies, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the initial public offering by iRhythm Technologies, Inc. iRhythm sold 7,238,235 shares…
Davis Polk Advises AC Immune SA on Its Initial Public Offering
Davis Polk advised AC Immune SA in connection with its $75.9 million U.S. initial public offering. AC Immune sold 6,900,000 of its common shares in the offering, which included 900,000…
Davis Polk Advises Aetna on the Sale of Medicare Advantage Assets to Molina Healthcare
Davis Polk is advising Aetna Inc. in connection with the sale by Aetna and Humana Inc. of certain of their respective Medicare Advantage assets to Molina Healthcare, Inc. for a total…